{"filing":{"accession_number":"0001193125-26-407817","cik":"0001826892","ticker":"BCAB","company_name":"BioAtla, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-23","primary_document":"bcab-20260923.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526407817/bcab-20260923.htm"},"events":[{"id":35837,"run_id":33028,"accession_number":"0001193125-26-407817","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Item 5.02(e) discloses multiple compensatory arrangements: Dr. Sievers' consulting agreement with contingent payments up to $159,000 through June 2027; reinstatement of retention bonuses for CFO Vasquez ($148,888 target) and CEO Dr. Short ($440,892 target) contingent on December 31, 2026 milestones; and new performance bonuses for both executives ($75,000 and $220,000 targets respectively) contingent on March 31, 2027 milestones. While Dr. Sievers' resignation is mentioned, the filing's primary focus under Item 5.02(e) is the compensatory arrangements themselves, including the Board's approval of bonus programs and their terms.","company_name":"BioAtla, Inc.","ticker":"BCAB","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":40033,"accession_number":"0001193125-26-407817","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Item 5.02(e) discloses multiple compensatory arrangements: Dr. Sievers' consulting agreement with contingent payments up to $159,000 through June 2027; reinstatement of retention bonuses for CFO Vasquez ($148,888 target) and CEO Dr. Short ($440,892 target) contingent on December 31, 2026 milestones; and new performance bonuses for both executives ($75,000 and $220,000 targets respectively) contingent on March 31, 2027 milestones. While Dr. Sievers' resignation is mentioned, the filing's primary focus under Item 5.02(e) is the compensatory arrangements themselves, including the Board's approval of bonus programs and their terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T21:17:36.832975+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40033,"accession_number":"0001193125-26-407817","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Item 5.02(e) discloses multiple compensatory arrangements: Dr. Sievers' consulting agreement with contingent payments up to $159,000 through June 2027; reinstatement of retention bonuses for CFO Vasquez ($148,888 target) and CEO Dr. Short ($440,892 target) contingent on December 31, 2026 milestones; and new performance bonuses for both executives ($75,000 and $220,000 targets respectively) contingent on March 31, 2027 milestones. While Dr. Sievers' resignation is mentioned, the filing's primary focus under Item 5.02(e) is the compensatory arrangements themselves, including the Board's approval of bonus programs and their terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T21:17:36.832975+00:00","company_name":"BioAtla, Inc.","ticker":"BCAB","filing_date":"2026-09-29"}]}